477 related articles for article (PubMed ID: 10557618)
1. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
[TBL] [Abstract][Full Text] [Related]
2. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
[TBL] [Abstract][Full Text] [Related]
3. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
[TBL] [Abstract][Full Text] [Related]
4. Medical devices; exemption from premarket notification and reserved devices; class I. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(10):2296-323. PubMed ID: 11010655
[TBL] [Abstract][Full Text] [Related]
5. Additions and Modifications to the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2016 Oct; 81(195):69668-77. PubMed ID: 27731962
[TBL] [Abstract][Full Text] [Related]
6. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
7. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
[TBL] [Abstract][Full Text] [Related]
8. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
[TBL] [Abstract][Full Text] [Related]
9. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
[TBL] [Abstract][Full Text] [Related]
10. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
11. Investigational new drug applications; clinical holds--FDA. Direct final rule.
Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
[TBL] [Abstract][Full Text] [Related]
12. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
[TBL] [Abstract][Full Text] [Related]
13. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
[TBL] [Abstract][Full Text] [Related]
14. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
[TBL] [Abstract][Full Text] [Related]
15. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
[TBL] [Abstract][Full Text] [Related]
16. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
17. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
[TBL] [Abstract][Full Text] [Related]
18. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
[TBL] [Abstract][Full Text] [Related]
19. Medical device reporting: manufacturer reporting, importer reporting, user facility reporting, distributor reporting. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(17):4112-21. PubMed ID: 11010653
[TBL] [Abstract][Full Text] [Related]
20. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
